PMID- 38371546
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240220
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Print)
IS  - 0019-5154 (Linking)
VI  - 68
IP  - 6
DP  - 2023 Nov-Dec
TI  - Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A 
      Real-World Observation Study.
PG  - 669-673
LID - 10.4103/ijd.ijd_551_23 [doi]
AB  - BACKGROUND: Methotrexate (MTX) in the therapy of psoriasis vulgaris (PV) is a 
      well and long-established treatment option. AIMS: To assess the long-term 
      experience of individual patients in the real world with regard to the efficacy 
      and safety of MTX in PV therapy. PATIENTS AND METHODS: In a retrospective study, 
      MTX as a weekly used monotherapy in PV was examined. Clinical data including the 
      Psoriasis Area Severity Index (PASI), prevalence of psoriatic-arthritis (PsA), 
      Investigator Global Assessment (IGA), laboratory parameters, occurrence of 
      adverse events (AEs), dosing of MTX and characteristics of patients treated for 
      at least 24 months were collected. RESULTS: A total of 55 patients with 247 
      patient-years under MTX therapy were included. The mean PASI reduction was 51.2% 
      with a significant (P < 0.001) improvement in the skin condition in the first 6 
      months of treatment, remaining stable thereafter. The mean MTX dose increased 
      from 11.8 +/- 3.7 mg to 12.9 +/- 3.8 mg in the first year of therapy, with a constant 
      mean dose in the following years. In 247 patient-years, no serious AE was 
      documented. Gastrointestinal side effects or fatigue were commonly detected. The 
      liver parameter alanine aminotransferase/ glutamate-pyruvate transaminase 
      (ALT/GPT) (baseline 35.8 +/- 22.0 U/L) increased after 3 years of therapy (42.0 +/- 
      22.4 U/L; P = 0.013) without clinical significance. CONCLUSION: In this patient 
      collective, MTX in low doses was effective and safe in long-term therapy. The 
      improved skin condition was steady and reached by an unvarying dose. New data 
      showed a better efficacy of MTX in higher doses; however, additional data must be 
      collected on the long-term efficacy and safety of MTX with a higher dose regime.
CI  - Copyright: (c) 2023 Indian Journal of Dermatology.
FAU - Wilsmann-Theis, Dagmar
AU  - Wilsmann-Theis D
AD  - From the Department of Dermatology and Allergy, University of Bonn, Bonn, 
      Germany.
FAU - Funk, Rhena
AU  - Funk R
AD  - From the Department of Dermatology and Allergy, University of Bonn, Bonn, 
      Germany.
FAU - Mossner, Rotraut
AU  - Mossner R
AD  - Department of Dermatology, University Medical Center Gottingen, Gottingen, 
      Germany.
FAU - Bieber, Thomas
AU  - Bieber T
AD  - From the Department of Dermatology and Allergy, University of Bonn, Bonn, 
      Germany.
FAU - Wenzel, Jorg
AU  - Wenzel J
AD  - From the Department of Dermatology and Allergy, University of Bonn, Bonn, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20240109
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC10869019
OTO - NOTNLM
OT  - Long-term treatment
OT  - methotrexate
OT  - psoriasis therapy
COIS- D. Wilsmann-Theis has been advisor and/or received speakers' honoraria or travel 
      expense reimbursements and/or received grants and/or participated in clinical 
      trials of the companies AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer 
      Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, 
      Lilly, Medac, Merck Sharp and Dohme Corp., Novartis, Pfizer, UCB Pharma, and VBL. 
      R. Funk has no conflicts of interest to declare. R. Mossner has been an advisor 
      and/or received speakers' honoraria and/or received grants and/or participated in 
      clinical trials of the following companies: Abbott/Abbvie, Allmirall, Biogen IDEC 
      GmbH, Bohringer-Ingelheim, Bristol Myers Squibb, Celgene, Essex Pharma GmbH, 
      Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly, Merck Serono GmbH, MSD SHARP and 
      DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. T. Bieber has no conflict 
      of interest relevant to this work. J.Wenzel has been an advisor and/or received 
      speakers' honoraria and/or received grants and/or participated in clinical trials 
      of the following companies: GSK, Novartis, Medac, Merck/Serono, Roche, Actelion, 
      Pfizer, Spirig, ArrayBio, Biogen.
EDAT- 2024/02/19 06:43
MHDA- 2024/02/19 06:44
PMCR- 2023/11/01
CRDT- 2024/02/19 04:28
PHST- 2024/02/19 06:44 [medline]
PHST- 2024/02/19 06:43 [pubmed]
PHST- 2024/02/19 04:28 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - IJD-68-669 [pii]
AID - 10.4103/ijd.ijd_551_23 [doi]
PST - ppublish
SO  - Indian J Dermatol. 2023 Nov-Dec;68(6):669-673. doi: 10.4103/ijd.ijd_551_23. Epub 
      2024 Jan 9.